Endotoxemia and tumor necrosis factor activity in dogs with naturally occurring parvoviral enteritis

被引:76
作者
Otto, CM [1 ]
Drobatz, KJ [1 ]
Soter, C [1 ]
机构
[1] UNIV PENN, SCH VET MED, EMERGENCY SERV, PHILADELPHIA, PA 19104 USA
关键词
D O I
10.1111/j.1939-1676.1997.tb00075.x
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
A prospective, nonrandomized study was performed to evaluate the role of endotoxin and tumor necrosis factor (TNF) in dogs with parvoviral enteritis. Seventeen dogs with naturally occurring parvoviral enteritis were enrolled in the study. Plasma samples were obtained for quantification of endotoxin and TNF on presentation and at 3 and 6 hours after therapy with either fluids prior to antibiotics, or fluids concurrently with antibiotics, All dogs received standard supportive therapy. Fourteen of 17 dogs had endotoxin in their plasma during the study period; 7 of 17 dogs had measurable TNF. No endotoxin or TNF was detectable in plasma from normal puppies. An increase in TNF activity was predictive of mortality (P =.041). There was a trend for increasing endotoxin activity to predict mortality (P =.0769). Animals that received antibiotics with fluids were significantly older than those that received fluids prior to antibiotics, and there was a trend for animals that received antibiotics with fluids to have a decrease in endotoxin activity after treatment (P =.054), Endotoxin and activation of the cytokine cascade are integral to the pathophysiology of parvoviral enteritis. Measures to limit endotoxemia and the systemic inflammatory response may improve survival.
引用
收藏
页码:65 / 70
页数:6
相关论文
共 26 条
[1]   AMERICAN-COLLEGE OF CHEST PHYSICIANS SOCIETY OF CRITICAL CARE MEDICINE CONSENSUS CONFERENCE - DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ ;
ABRAMS, JH ;
BERNARD, GR ;
BIONDI, JW ;
CALVIN, JE ;
DEMLING, R ;
FAHEY, PJ ;
FISHER, CJ ;
FRANKLIN, C ;
GORELICK, KJ ;
KELLEY, MA ;
MAKI, DG ;
MARSHALL, JC ;
MERRILL, WW ;
PRIBBLE, JP ;
RACKOW, EC ;
RODELL, TC ;
SHEAGREN, JN ;
SILVER, M ;
SPRUNG, CL ;
STRAUBE, RC ;
TOBIN, MJ ;
TRENHOLME, GM ;
WAGNER, DP ;
WEBB, CD ;
WHERRY, JC ;
WIEDEMANN, HP ;
WORTEL, CH .
CRITICAL CARE MEDICINE, 1992, 20 (06) :864-874
[2]   PROGNOSTIC VALUES OF TUMOR-NECROSIS-FACTOR CACHECTIN, INTERLEUKIN-1, INTERFERON-ALPHA, AND INTERFERON-GAMMA IN THE SERUM OF PATIENTS WITH SEPTIC SHOCK [J].
CALANDRA, T ;
BAUMGARTNER, JD ;
GRAU, GE ;
WU, MM ;
LAMBERT, PH ;
SCHELLEKENS, J ;
VERHOEF, J ;
GLAUSER, MP .
JOURNAL OF INFECTIOUS DISEASES, 1990, 161 (05) :982-987
[3]   STRATEGIES FOR BLOCKING THE SYSTEMIC EFFECTS OF CYTOKINES IN THE SEPSIS SYNDROME [J].
CHRISTMAN, JW ;
HOLDEN, EP ;
BLACKWELL, TS .
CRITICAL CARE MEDICINE, 1995, 23 (05) :955-963
[4]   PLASMA TUMOR NECROSIS FACTOR LEVELS IN PATIENTS WITH PRESUMED SEPSIS - RESULTS IN THOSE TREATED WITH ANTILIPID-A ANTIBODY VS PLACEBO [J].
DEGROOTE, MA ;
MARTIN, MA ;
DENSEN, P ;
PFALLER, MA ;
WENZEL, RP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1989, 262 (02) :249-251
[5]  
DIMMITT R, 1991, CANINE PRACT, V16, P23
[6]   EVALUATION OF A NOVEL DIAGNOSTIC-TEST FOR CANINE PARVOVIRUS [J].
DRANE, DP ;
HAMILTON, RC ;
COX, JC .
VETERINARY MICROBIOLOGY, 1994, 41 (03) :293-302
[7]   A HIGHLY SENSITIVE CELL-LINE, WEHI-164 CLONE 13, FOR MEASURING CYTOTOXIC FACTOR TUMOR-NECROSIS-FACTOR FROM HUMAN-MONOCYTES [J].
ESPEVIK, T ;
NISSENMEYER, J .
JOURNAL OF IMMUNOLOGICAL METHODS, 1986, 95 (01) :99-105
[8]   EFFECT OF ANTIBIOTIC CLASS AND CONCENTRATION ON THE RELEASE OF LIPOPOLYSACCHARIDE FROM ESCHERICHIA-COLI [J].
EVANS, ME ;
POLLACK, M .
JOURNAL OF INFECTIOUS DISEASES, 1993, 167 (06) :1336-1343
[9]  
GLICKMAN LT, 1985, J AM VET MED ASSOC, V187, P589
[10]  
ISOGAI E, 1989, JPN J VET SCI, V51, P597